First marketing authorisation of a COVID-19 Vaccine (BioNTech)
messages in brief
|
22/12/2020
The authorised indication and adverse reactions known from clinical studies are listed in the product information leaflet. For information in other European languages, please consult the Union Register of medicinal products on the website of the European Commission.
Further inquiry note
Page last modified:
23/12/2020